olesalers, mail order, government and national retail drug and food store chains utilizing a small team of sales and marketing professionals. During 2014, on a combined business, the company expanded its generic product line with the launch of approximately 550 generic products worldwide. Strategy: The company’s strategy in the U.S. is to develop pharmaceuticals that are difficult to formulate or manufacture or would complement or broaden its existing product lines. Anda Distribution This segment distributes generic and brand pharmaceutical products manufactured by third parties, as well as by the company, primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians’ offices. Sales are principally generated through the company’s national accounts relationships, an in-house telemarketing staff and through internally developed ordering systems. Additionally, the company sells to members of buying groups, which are independent pharmacies that join together to improve their buying power. The company also distributes its own products and collaborative partners’ products. This segment distributes products for approximately 340 suppliers and is focused on providing next-day delivery and responsive service to its customers. As of December 31, 2014, the company distributed approximately 12,650 stock-keeping units through its Anda Distribution segment. Customers In the company’s North American Brands and North American Generics and International operations, the company sells its generic and brand pharmaceutical products primarily to drug wholesalers, retailers, and distributors, including national retail drug and food store chains, hospitals, clinics, mail order retailers, government agencies, and managed healthcare providers, such as health maintenance organizations and other institutions. In the company’s Anda Distribution business, the company distributes generic and brand pharmaceutical products to independent pharmacies, alternate care providers (hospitals, nursing homes, and mail order pharmacies), pharmacy chains, physicians’ offices, and buying groups. The company’s customers include AmerisourceBergen Corporation; McKesson Corporation; Cardinal Healthcare, Inc.; and Walgreens. Acquisitions In July 2014, the company completed an agreement to acquire Furiex Pharmaceuticals, Inc. In April 2014, the company acquired Silom Medical Company, a privately held generic pharmaceutical company focused on developing and marketing therapies in Thailand. Business Strategy The company applies three major strategies to achieve growth for its North American Brands, and North American Generics and International businesses, such as internal development of differentiated and high-demand products, including in certain circumstances as it relates to generics, requiring patents associated with these products; the establishment of strategic alliances and collaborations; and the acquisition of products and companies that complement its business. Government Regulation and Regulatory Matters The company is subject to extensive, complex, and evolving regulation by the federal government, principally the U.S. Food and Drug Administration, and to a lesser extent, by the U.S. Drug Enforcement Administration, Occupational Safety and Health Administration, and state government agencies, as well as by various regulatory agencies in foreign countries where its products or product candidates are being manufactured and/or marketed. The Federal Food, Drug and Cosmetic Act; the Controlled Substances Act; and other federal statutes and regulations govern or influence the testing, manufacturing, packing, labeling, storing, record keeping, safety, approval, advertising, promotion, sale, and distribution of the company’s products. Competition The company’s major competitors include Teva Pharmaceutical Industries, Ltd.; Mylan Inc.; and Sandoz, Inc. (a division of Novartis AG). In its Anda Distribution segment, the company competes with McKesson Corporation, AmerisourceBergen Corporation, and Cardinal Health, Inc.
actavis plc (ACT:New York)
Morris Corporate Center III
400 Interpace Parkway
Parsippany, NJ 07054
|Bristol-Myers Squibb Co||$66.48 USD||+1.88|
|GlaxoSmithKline PLC||1,446 GBp||-10.00|
|Medtronic PLC||$76.70 USD||+0.38|
|Novo Nordisk A/S||kr387.10 DKK||-2.00|
|Valeant Pharmaceuticals International Inc||C$300.08 CAD||+3.64|
|View Industry Companies|
Sponsored Financial Commentaries
To contact ACTAVIS PLC, please visit www.actavis.ie. Company data is provided by Capital IQ. Please use this form to report any data issues.